Angiogenesis inhibitors

Cancer Practice

Volumn 6, Issue 1, 1998, Pages 60-62

  Hui, Yuk Fung ^a   Ignoffo, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIN; BATIMASTAT; CORTISONE ACETATE; CYTOKINE; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GANGLIOSIDE; GROWTH FACTOR; HAPTOGLOBIN; INTERLEUKIN 12; INTERLEUKIN 8; MARIMASTAT; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; OKADAIC ACID; OXYGEN; PENTOSAN POLYSULFATE; PROTEINASE; RECEPTOR; SURAMIN; TAMOXIFEN; TECOGALAN; TETRAHYDROCORTISOL; THALIDOMIDE; THROMBOCYTE FACTOR 4; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; ENZYME INHIBITOR; GROWTH INHIBITOR;

ANGIOGENESIS; CHILL; CLINICAL TRIAL; FEVER; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SHORT SURVEY; TERATOGENICITY; THROMBOCYTOPENIA; TUMOR GROWTH; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0031893619     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1998.1998006060.x     Document Type: Short Survey

References (27)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Tapper D, Langer R, Bellows R, et al. Angiogesis capacity as a diagnostic marker for human eye tumors. Surgery 1979; 86:36-40.
3. Srivastava A, Laidler P, Hughes LE, et al. Neovascularization in human cutaneous melanoma: A quantitative morphological and Doppler ultrasound study. Eur J Cancer Clin Oncol 1986; 22: 1205-1209.
4. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
5. Wakui S, Furusato M, Sasaki H, et al. Tumor angiogenesis in prostatic carcinoma with and without bone metastases: A morphometric study. J Pathol 1992; 168:257-262.
6. Nguyen M, Watanabe H, Hudson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-361.
7. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factors: A potential role of T cells in angiogenesis. Cancer Res 1995; 55:4140-4145.
8. Ito N, Kawata S, Tamura S, et al. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995; 89:45-48.
9. Iruela-Arispe ML, Dvorak HF. Angiogenesis: A dynamic balance of stimulators and inhibitors. Thromb Haemost 1997; 78:672-679.
10. Saclarides TJ. Angiogenesis in colorectal cancer. Surg Clin N Am 1997; 77:253-260.
11. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24: 203-218.
12. Auerbach W, Auerbach R. Angiogenesis inhibition: A review. Pharmacol Ther 1994; 65:265-311.
13. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteinases and their inhibitors in tumor invasion, maturation and angiogenesis. Eur Respir J 1994; 7:2062-2072.
14. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3:89-96.
15. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against basic fibroblast growth factors. Cancer Res 1991; 51:6180-6184.
16. Herbert JM, Cottineau M, Driot F, et al. Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem Pharmacol 1988; 37:4281-4288.
17. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993: 85:1585-1592.
18. Sato Y, Abe M, Takaki R. Platelet factor 4 blocks the binding of basic fibroblast growth factors to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990; 172:595-600.
19. Maione TE, Gray GS, Hunt AJ et al. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991; 51:2077-2083.
20. Takano S, Gately S, Neville ME et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54: 2654-2660.
21. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
22. Tanaka NG, Sakamoto N, Korenaga H et al. The combination of a bacterial polysaccharide and tamoxifen inhibits angiogenesis and tumor growth. Int J Radiat Biol 1991; 60:79-83.
23. Inoue K, Korenaga H, Tanaka NG et al. The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate. Carbohydr Res 1988; 181:135-142.
24. Figg WD, Pluda JM, Wyvill K et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Clin Res 1994; 42:255. Abstract.
25. Low JA, Johnson MD, Bone EA, et al. The matrix metalloproteinase inhibitor bastimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996; 2:1207-1214.
26. Boasberg P, Harbaugh B, Roth B, et al. Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 1996; 15:258. Abstract.
27. Wojtowicz-Praga S, Low J, Dickson R et al. Pharmacokinetics (PK) of marimastat (BB-2516), a novel matrix metalloproteinase inhibitor (MMPI) administered orally to patients with metastatic lung cancer. Proc Am Soc Clin Oncol 1996; 15:490. Abstract.